Upstream Processing

GSK will invest in an additional downstream isolation facility for amoxicillin production in Singapore.

Australian company, Genea Biocells, will open a facility in San Diego, California for cell and culture-media manufacturing and R&D.

IDT Biologika acquired Aeras' vaccine manufacturing facility, and the companies will work together on tuberculosis vaccine development.

Novasep's new antibody drug conjugate facility at its site in Le Mans, France will be commissioned in 2016.

Contract service providers share insights on biopharma market developments and the implications of biosimilar drug approvals.

EMD Millipore debuts a new cell-culture media compacting technology that will turn messy, dry powders into granules.

Biopharma companies on both sides of the Atlantic ship more of their assay testing to outside service providers.

Medicago's new production facility will make plant-based vaccines and therapeutics.

Choosing the optimal protein expression vector depends on strain, promoter, and a number of other factors.

This article presents first-hand perspectives from industry users to suppliers of single-use sensors.

Making the switch from batch to continuous manufacturing requires a thorough understanding of the process.

It is important to understand degradation and processing to maintain product stability in biologics.

EMD Millipore will provide process development services for Precision Biologics’ preclinical monoclonal antibody.

They may not be glamorous, but buffers play an important role in biopharma manufacturing.

The use of commercially available media to achieve high titer in early process development is discussed.

Catalent announced that it would partner with Mitsubishi Gas Chemical Company, and its subsidiary MGC Pharma, to promote GPEx technology, a high-titer vector for stable mammalian cell lines.

Sanofi will tap into Boehringer Ingelheim’s therapeutic monoclonal antibody manufacturing capabilities.

Single-use components aid efficiency in automated personalized therapy manufacturing.

Improving efficiency, value chain, quality, and protein complexity with advanced bioprocess development.

Protein Sciences will evaluate sourcing Flublok from its Japanese licensee, UMN Pharma, which already runs a large-scale facility for the vaccine.

The Cell Therapy Catapult, a UK non-profit center for advancing cell and gene therapies, will manage the manufacturing center, which will be used for late-phase clinical trials and commercial supply.

Under an NIH contract, Paragon Bioservices will design a manufacturing process for recombinant human rhE-selectin protein.

Representatives from industry supplier companies address innovations, reliability, barriers to adoption, and the role of singIe-use bioreactors in bioprocessing.

Challenges remain for virus removal and validation.

Eppendorf's Cell Culture Consumables have an ISO class/GMP class C clean room production standard.

Fed-batch processes were scaled up from traditional bench-scale bioreactors to large-scale single-use systems.

Careful selection of downstream processing conditions is a must.

Different approaches to prepare highly concentrated feed media for fed-batch Chinese hamster ovary cell culture are evaluated.

New approaches to vaccine production are targeting rapid supply for pandemic situations and broadly effective therapeutic treatments.

Gallus BioPharmaceuticals enters a cell line optimization and manufacturing agreement with Omni Bio Pharmaceutical.